Properties of Concurrent Programs

A program property is a predicate on programs. In this paper we explore program properties of the form U -> V where U and V are either predicates on states of a program or program properties, and -> satisfies three rules that are also used in reasoning about sequential programs and safety properties of parallel programs. We show how such properties can be used to reason about concurrent programs

On group extensions

Thesis (M.A.)--Boston University Bibliography

A Primer for Program Composition Notation

This primer describes a notation for program composition. Program composition is putting programs together to get larger ones. PCN (Program Composition Notation) is a programming language that allows programmers to compose programs so that composed programs execute efficiently on uniprocessors, distributed-memory multicomputers or shared-memory multiprocessors. (Revised December 12, 1990

Mach-Based Channel Library

[No Abstract

Systematic composition of distributed objects: Processes and sessions

We consider a system with the infrastructure for the creation and interconnection of large numbers of distributed persistent objects. This system is exemplified by the Internet: potentially, every appliance and document on the Internet has both persistent state and the ability to interact with large numbers of other appliances and documents on the Internet. This paper elucidates the characteristics of such a system, and proposes the compositional requirements of its corresponding infrastructure. We explore the problems of specifying, composing, reasoning about and implementing applications in such a system. A specific concern of our research is developing the infrastructure to support structuring distributed applications by using sequential, choice and parallel composition, in the anarchic environment where application compositions may be unforeseeable and interactions may be unknown prior to actually occurring. The structuring concepts discussed are relevant to a wide range of distributed applications; our implementation is illustrated with collaborative Java processes interacting over the Internet, but the methodology provided can be applied independent of specific platforms

Patient and Disease-Specific Induced Pluripotent Stem Cells for Discovery of Personalized Cardiovascular Drugs and Therapeutics.

Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production of limitless supply of patient-specific somatic cells that enable advancement in cardiovascular precision medicine. Over the past decade, researchers have developed protocols to differentiate iPSCs to multiple cardiovascular lineages, as well as to enhance the maturity and functionality of these cells. Despite significant advances, drug therapy and discovery for cardiovascular disease have lagged behind other fields such as oncology. We speculate that this paucity of drug discovery is due to a previous lack of efficient, reproducible, and translational model systems. Notably, existing drug discovery and testing platforms rely on animal studies and clinical trials, but investigations in animal models have inherent limitations due to interspecies differences. Moreover, clinical trials are inherently flawed by assuming that all individuals with a disease will respond identically to a therapy, ignoring the genetic and epigenomic variations that define our individuality. With ever-improving differentiation and phenotyping methods, patient-specific iPSC-derived cardiovascular cells allow unprecedented opportunities to discover new drug targets and screen compounds for cardiovascular disease. Imbued with the genetic information of an individual, iPSCs will vastly improve our ability to test drugs efficiently, as well as tailor and titrate drug therapy for each patient

The international growth of emerging market firms : evidence from a natural experiment

The recent international growth of some firms from emerging markets has attracted the attention of academics and managers alike. How do such emerging market firms achieve growth in international markets despite lacking foreign market knowledge and international competitiveness, and despite facing weak institutions in their home countries? The authors address this question by proposing a new concept—global market capital, the set of assets that prepare emerging market firms to compete globally. Global market capital consists of three elements: leadership capital (at the individual level), foreign marketing and financial capital (at the firm level), and network capital (at the inter-firm level). The authors argue that, taken together, these elements enable emerging market firms to overcome their weaknesses in foreign market knowledge, international competitiveness and home institutions. In particular, the authors highlight the prominent role that leadership capital, specifically CEOs’ foreign market experience, plays in helping emerging market firms grow internationally. The authors test their thesis using uniquely compiled data on Indian firms from the Bombay Stock Exchange 500 index. The Indian context helps to set up a natural experiment in which the independent variables of interest are measured prior to a major sudden and unanticipated regulatory shift in India’s outward investment policy and the dependent variable (international growth) is measured after this policy shift. Results from the paper highlight the crucial role of leadership capital in driving international growth both directly and through its synergistic interaction with the other elements of global market capital